As I predicted yesterday, there has been nary a story on the US Preventive Services Task Force’s new statement that the evidence isn’t in yet on nine ways to look for signs of coronary heart disease in people without symptoms.
Journalists – many of whom sang the praises of at least two of those methods (the CRP test and coronary artery calcium CT scans) – either aren’t aware or don’t care about cautious, evidence-based recommendations from the USPSTF.
The only stories I’ve seen were by the Wall Street Journal health blog and by MedPage Today which did a
story and a blog posting.
On the MedPageToday blog, Peggy Peck wrote:
This is a setback for CRP believers, a group whose numbers swelled significantly when Paul Ridker reported last November that giving “healthy” adults who had hs-CRP of 2.0 mg/L or higher a potent statin for less than 2 years reduced “the rate of MI stroke, arterial revascularization, or cardiovascular death was 44% (P<0.00001)."
Those findings came from the JUPITER trial and when they were announced there were lots of pundits predicting that hs-CRP would become everyone’s favorite test and that maybe it really was time to consider putting statins in the water.Since last November churning out additional analyses from JUPITER has become something of a cottage industry and some weeks it is difficult to pick up a heart journal or attend a cardiology meeting without being confronted with yet another JUPITER result.
In my opinion it had gotten out-of-hand, so about a month ago I started telling every PR person so sent me the latest breathless JUPITER press release that “I am done with JUPITER.”
But here I am, once again, strumming the JUPITER tune. There’s no escaping it.
Well, there may no escaping it for journalists like Peck.
But almost every other journalist and news organization – so far – has found such news very easy to escape.
It seems to me that when previously highly-promoted approaches are judged to be not ready for prime time by an independent panel with no axe to grind, that’s news.
Opinions on other issues in news, journals, PR, advertising, marketing
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
dw
October 23, 2009 at 8:38 amNot surprising there’s no escaping JUPITER with the marketing machinery in place within the pharmaceutical industry. It’s unfortunate that the development of medical treatments has become mostly business since George W. limited government funding for basic science/medical research and forced researchers to turn to private industry for support. Seems to me the mainstream is not thinking critcally and paying attention to who is funding these trials and what their motivations are. I’m not saying we should throw out the baby with bathwater, but I can’t find the evidence from an unbiased source. It has become exceedingly challenging in the past two decades separating the wheat from the chaff with “scientific” studies. It seems we haven’t made any real progress in medicine since the 1980’s when patient safety came before profits.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like